admin
April 9, 2026
An investor once reviewed two startups in the same week. Both had regulatory issues. One deal moved forward.
The other was declined immediately.
April 8, 2026
An investor once reviewed a data room with over 300 regulatory documents. Policies. SOPs. Test reports. Slide decks. Validation summaries. Everything looked thorough. Then a single question changed the entire deal: “Where is the evidence that this pathway actually holds?”
April 7, 2026
An investor once asked a founder a simple question: “What happens if FDA disagrees with your pathway?” The room went quiet. Not because the answer was confidential.
Because there was no answer. The deal didn’t collapse immediately.
But it never recovered.
April 6, 2026
An investor once said: “We didn’t pass on the company because the product was weak.We passed because we couldn’t tell if it would ever reach the […]
